Dateline City:
WHITEHOUSE STATION, N.J.
Clinical Findings Support Initiation of C-EDGE Phase 3 Program
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced interim results from the ongoing C-WORTHy study,
a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of
an all-oral, once-daily regimen combining MK-5172, an investigational
hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an
investigational HCV NS5A replication complex inhibitor, among patients
with chronic HCV Genotype 1 infection (GT1).
Language:
English
Contact:
MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more